Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.56 |
| ▸ | CA9 | Q16790 | 5/20 | 0.56 |
| ▸ | CA1 | P00915 | 4/20 | 0.56 |
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP3 | P08254 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.39 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 2/20 | 0.38 |
| ▸ | CES1 | P23141 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL498626 | 0.95 | CA12 (0.52) | CA12CA9CA1MMP1MMP2 | |
| SCHEMBL5826286 | 0.92 | CA12 (0.48) | CA12CA9CA1MMP1MMP2 | |
| SCHEMBL6163862 | 0.90 | CA12 (0.50) | CA12CA9CA1MMP1MMP2 | |
| SCHEMBL6162958 | 0.90 | CA12 (0.50) | CA12CA9CA1MMP1MMP2 | |
| SCHEMBL15766566 | 0.90 | CA12 (0.50) | CA12CA9CA1MMP1MMP2 | |
| SCHEMBL6131093 | 0.90 | CA12 (0.50) | CA12CA9CA1MMP1MMP2 | |
| SCHEMBL6162968 | 0.90 | CA12 (0.50) | CA12CA9CA1MMP1MMP2 | |
| SCHEMBL6164843 | 0.90 | CA12 (0.50) | CA12CA9CA1MMP1MMP2 | |
| SCHEMBL498026 | 0.90 | CA12 (0.59) | CA12CA9CA1MMP1MMP2 | |
| SCHEMBL6547338 | 0.89 | DNM1 (0.50) | CA12CA9CA1MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9482923-B2 | Colored composition and image display structure | FUJIFILM CORPORATION (JP) | 2016-11-01 | — | — | US | claimed |
| EP-1379238-A1 | FAVORABLE MODULATION OF HEALTH-RELATED QUALITY OF LIFE AND HEALTH-RELATED QUALITY-ADJUSTED TIME-TO-PROGRESSION OF DISEASE IN PATIENTS WITH PROSTATE CANCER | Abbott Laboratories (US) | 2004-01-14 | — | — | EP | claimed |
| US-20030092757-A1 | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer | ABBOTT LABORATORIES | 2003-05-15 | — | — | US | claimed |
| WO-2002085351-A1 | FAVORABLE MODULATION OF HEALTH-RELATED QUALITY OF LIFE AND HEALTH-RELATED QUALITY-ADJUSTED TIME-TO-PROGRESSION OF DISEASE IN PATIENTS WITH PROSTATE CANCER | ABBOTT LABORATORIES (US) | 2002-10-31 | — | — | WO | claimed |
| US-11938233-B2 | 1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof | UNIVERSITÄTSKLINIKUM REGENSBURG (DE) | 2024-03-26 | — | — | US | disclosed |
| US-20220054671-A1 | 1,7-DIARYL-1,6-HEPTADIENE-3,5-DIONE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF | UNIVERSITÄTSKLINIKUM REGENSBURG (DE) | 2022-02-24 | — | — | US | disclosed |
| US-11191855-B2 | 1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof | UNIVERSITÄTSKLINIKUM REGENSBURG (DE) | 2021-12-07 | — | — | US | disclosed |
| EP-3135110-B1 | 1,7-DIARYL-1,6-HEPTADIEN-3,5-DION DERIVATIVES, METHODS OF MAKING AND USING THE SAME | TRIOPTOTEC GMBH (DE) | 2019-07-10 | — | — | EP | disclosed |
| US-20180272013-A1 | 1,7-DIARYL-1,6-HEPTADIENE-3,5-DIONE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF | UNIVERSITÄT SALZBURG (AT) | 2018-09-27 | — | — | US | disclosed |
| EP-2753329-B1 | 1,5-NAPHTHYRIDINE DERIVATIVES AS MELK INHIBITORS | ONCOTHERAPY SCIENCE INC (JP) | 2017-08-09 | — | — | EP | disclosed |
| WO-2017032892-A1 | 1,7-DIARYL-1,6-HEPTADIENE-3,5-DIONE DERIVATIVES, METHODS FOR THE PRODCUTION AND USE THEREOF | UNIVERSITÄTSKLINIKUM REGENSBURG (DE) | 2017-03-02 | — | — | WO | disclosed |
| EP-3135110-A1 | 1,7-DIARYL-1,6-HEPTADIEN-3,5-DION DERIVATIVES, METHODS OF MAKING AND USING THE SAME | Universitätsklinikum Regensburg (DE) | 2017-03-01 | — | — | EP | disclosed |
| US-5306808-A | Endothelin derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-04-26 | — | — | US | disclosed |
| EP-0574846-A2 | Imidazopyridines as angiotensin II antagonistes | MERCK PATENT GmbH (DE) | 1993-12-22 | — | — | EP | disclosed |
| EP-0574355-A1 | Phosphinyloxy propanaminium inner salt derivatives | SANDOZ LTD. (CH) | 1993-12-15 | — | — | EP | disclosed |
| EP-0569592-A1 | CARBOSTYRIL DERIVATIVE AND PLATELET AGGLUTINATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-11-18 | — | — | EP | disclosed |
| EP-0547317-A1 | Endothelin antagonists | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-06-23 | — | — | EP | disclosed |
| EP-0499266-A1 | Endothelin antagonist | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-08-19 | — | — | EP | disclosed |
| US-4950648-A | SUBSTITUTED PYRIDO(2,3-D) OR PYRIMIDO(4,5-D) PYRIMIDINE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1990-08-21 | — | — | US | disclosed |
| EP-0316668-A2 | Use of a tetrahydro-pyrido(2,3-d)pyrimidine for obtaining an analgetic agent | MERCK PATENT GmbH (DE) | 1989-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220054671-A1 | 1,7-DIARYL-1,6-HEPTADIENE-3,5-DIONE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF | DHPS, SQLE, CYP51A1 | CA12 3178/4885CA9 3358/4885CA1 2560/4885 |
| US-20180272013-A1 | 1,7-DIARYL-1,6-HEPTADIENE-3,5-DIONE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF | DHPS, SQLE, CYP51A1 | CA12 3178/4885CA9 3358/4885CA1 2560/4885 |
| US-20030092757-A1 | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer | KLK3, ACP3, BPHL | CA12 2629/4885CA9 2984/4885CA1 4501/4885 |
| US-11191855-B2 | 1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof | DHPS, SQLE, CYP51A1 | CA12 3178/4885CA9 3358/4885CA1 2560/4885 |
| US-11938233-B2 | 1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof | DHPS, SQLE, CYP51A1 | CA12 3178/4885CA9 3358/4885CA1 2560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.